ArticleThe Journal of allergy and clinical immunology2023
Single-cell RNA sequencing defines disease-specific differences between chronic nodular prurigo and atopic dermatitis.
Article in The Journal of allergy and clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- IL31 identified as a key genetic risk factor for prurigo nodularis.The Journal of allergy and clinical immunology · 2025Pooled it
- Immunopathogenesis of itch: an integrative framework for chronic pruritus.JID innovations : skin science from molecules to population health · 2026Review
- The State of the Art in Chronic Prurigo Nodularis.Dermatology and therapy · 2026Review
- [Chronic prurigo: overview of pathophysiology, diagnosis, and treatment].Dermatologie (Heidelberg, Germany) · 2026Review
- Single-cell spatial transcriptomic analysis of human skin anatomy.Nature genetics · 2026Article
- Hidden immune memory niches in inflammatory skin diseases.bioRxiv : the preprint server for biology · 2026Article
- Exploring the impact of IL-2 cytokine family on skin barrier function: pathophysiology and therapeutic strategies.Molecular biology reports · 2026Review
- Type 2 Inflammatory Diseases: The Crossroads of Immunity and Metabolism.Research (Washington, D.C.) · 2026Review
- Interleukin-24 in type 2 immune diseases.Frontiers in immunology · 2026Review
- Obesity-Associated Cardiac Fibrosis: Mechanisms and Emerging Therapeutic Targets.Vascular health and risk management · 2026Review
- Identification and experimental validation of CCL26 as a core comorbid gene and biomarker for atopic dermatitis and allergic asthma via machine learning and multi-omics analysis.Frontiers in immunology · 2026Article
- IL-13 and skin fibrosis in inflammatory skin diseases.Frontiers in immunology · 2026Review
- Identification of disease-specific regulatory networks in prurigo nodularis versus atopic dermatitis through ATAC/RNA single-nucleus profiling.The Journal of allergy and clinical immunology · 2025Article
- Whole-genome sequencing reveals rare and structural variants contributing to psoriasis and identifies CERCAM as a risk gene.Cell genomics · 2025Article
- A basophil-fibroblast pro-inflammatory axis fuels type 2 skin inflammation.Cell reports · 2025Article
- Bioinformatic Analysis of the Value of Mitophagy and Immune Responses in Corneal Endothelial Dysfunction.Current issues in molecular biology · 2025Article
- Structure and function of therapeutic antibodies approved by the US FDA in 2024.Antibody therapeutics · 2025Review
- scExtract: leveraging large language models for fully automated single-cell RNA-seq data annotation and prior-informed multi-dataset integration.Genome biology · 2025Article
- Dupilumab treatment for prurigo nodularis: a retrospective study of 76 patients.Postepy dermatologii i alergologii · 2025Article
- Article
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic nodular prurigo (CNPG) is an inflammatory skin disease that is maintained by a chronic itch-scratch cycle likely rooted in neuroimmunological dysregulation. This condition may be associated with atopy in some patients, and there are now promising therapeutic results from blocking type 2 cytokines such as IL-4, IL-13, and IL-31.
objectivesThis study aimed to improve the understanding of pathomechanisms underlying CNPG as well as molecular relationships between CNPG and atopic dermatitis (AD).
methodsWe profiled skin lesions from patients with CNPG in comparison with AD and healthy control individuals using single-cell RNA sequencing combined with T-cell receptor sequencing.
resultsWe found type 2 immune skewing in both CNPG and AD, as evidenced by CD4
conclusionsThese data show that CNPG does not harbor the strong disease-specific immune activation pathways that are typically found in AD but is rather characterized by upregulated stromal remodeling mechanisms that might have a direct impact on itch fibers.
Indexed as
Identifiers
37210042What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.